Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)
Not Applicable
Withdrawn
- Conditions
- Hepatocellular CarcinomaMetastatic Liver Cancer
- Interventions
- Device: BioTraceIO 360
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Techsomed Medical Technologies LTD
- Registration Number
- NCT05641922
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Liver CancerHepatocellular Carcinoma
- Interventions
- Device: BioTraceIO 360
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Techsomed Medical Technologies LTD
- Target Recruit Count
- 40
- Registration Number
- NCT05582018
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Completed
- Conditions
- Carcinoma, HepatocellularMetastatic Liver Cancer
- Interventions
- Device: BioTraceIO Lite
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Techsomed Medical Technologies LTD
- Target Recruit Count
- 65
- Registration Number
- NCT04970212
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Stanford Medicine, Stanford, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath